Cerep offers tools and knowledge to help those companies discover and develop new drugs without having to start from scratch. It also developed a library of compounds that includes promising substances and drug candidates developed with Bristol-Myers Squibb and Sanofi-Aventis. Customers use Cerep's expertise in compound profiling, computational chemistry, in vitro and in vivo pharmacology, and pharmacoinformatics to cut to the chase and develop successful drug candidates.

Since its founding in 2004, Anthera Pharmaceuticals' operations have consisted primarily of research and development activities. A biopharmaceutical company, Anthera Pharmaceuticals develops drug treatments for respiratory, cardiovascular, and immunological diseases. Its current candidates, which are in various phases of clinical development, include therapies for acute coronary syndrome (inflammation of heart muscle), lupus, and sickle cell disease. The company also has treatments for asthma and dermatitis in earlier stages of development. The company filed an initial public offering (IPO) in mid-2009.

Founded in 1981, Generics (UK) Limited is a subsidiary of Mylan, the world's third largest generic drug maker. Generics (UK) Limited covers the pharmaceutical business. The name pretty much says it all. Generics (UK) Limited is one of the UK's largest generic pharmaceutical manufacturers, offering a line of more than 350 products sold to pharmacy retailers, hospitals, and wholesale customers. The company makes generic equivalents of such drugs as acid reflux remedy Pepcid, antibiotic Cipro, and allergy treatment Zyrtec.

Quintiles Transnational has plenty to CRO about. One of the world's top contract research organizations (CROs), with operations in more than 50 countries, it helps drug and medical device companies develop and sell their products. The firm provides a comprehensive range of clinical trials management services, including patient recruitment, data analysis, laboratory testing, and regulatory filing. Its consulting unit offers strategic advice at every stage of drug discovery and development, and its Innovex subsidiary is a contract sales organization providing sales personnel to promote approved products. An investment group led by founder and CEO Dennis Gillings owns the company.

ROHTO Pharmaceutical Co., Ltd. company was founded by Yasutami Yamada in 1899 as Shintendo Yamada Anmin Pharmacy. Later, it changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical is headquartered in Osaka, Japan. Rohto Pharmaceutical Co., Ltd. engages in the manufacture and marketing of pharmaceutical and other healthcare products in Japan and internationally. It primarily offers eye care, skin care, and oral medicine and supplement products. The company's eye care products include eye drops, eye wash preparations, and contact lens care products. Its eye care products spreads moisture over the surface of the eyes, suppresses allergy and works on ocular itching, as well as are used for the treatment of sties and conjunctivitis, inflammation or itching caused by bacteria on lenses, and eye disease causing pollens and house dust.Rohto company's skin care products include dermal medicines, which are used for the treatment of dry skin and females' anorectal discomforts; lip care products that are used for the prevention of dry, sore, and roughness of lips; and hand, body, sun, and acne care products. Rohto Pharmaceutical's oral medicine and supplement products include `Pansion' brand products, which are primarily used for the treatment of gastric discomfort, mucosal repair agents and stomachics for improving damaged gastric mucosa, stomach pain, and heartburn and other hyperacidity-related symptoms. It also offers a range of test products, including blood sugar testing kits, ovulation self-test kits, and pregnancy self-test kits; and denture cleansers.

Fortitech, Inc. company makes nutrient-rich premixes -- chock full of vitamins, minerals, and other ingredients -- that food and beverage makers add to their products to improve their nutritional content. Companies use Fortitech's custom-made nutrient premixes to fortify a variety of foods and other products, including baby formula, cereals, sports drinks, nutrition bars, supplements, snack foods, noodles, and rice. The firm works with its customers to develop blends that target various health conditions or demographic groups; it then makes and distributes the premixes, which come in both liquid and powder form, from facilities located around the world.

Vetoquinol S.A. was founded in 1933 and is based in Lure, France. Vétoquinol S A engages in the research and development, manufacture, marketing, and sale of medicines and nutraceuticals for animal health. It offers Marbocyl, an antibiotic for various species; Tolfédine and Tolfine anti-inflammatories for minimizing animal pain; and Prilium, an oral daily administration formula for cardiovascular treatment. The company’s products are used for dogs, cats, cattle, and pigs. It sells its products in Europe, North America, Africa, the Middle East, and the Pacific Asia. Vétoquinol S A was formerly known as Laboratoires Biochimiques de l’Est and changed its name to Vetoquinol S.A. in 1962.

Dey, L.P. company, a subsidiary of generic drugmaker Mylan, makes prescription drugs for the treatment of allergies and respiratory diseases. Dey markets EpiPen autoinjectors, used by patients to self-administer epinephrine for severe allergic reactions. Its premeasured unit-dose inhalation products include treatments for asthma and chronic obstructive pulmonary disease (COPD). These treatments, called bronchodialators, are used in air-driven breathing devices called nebulizers and include branded DuoNeb and Perforomist products. It also offers several non-branded generic nebulizer treatments. A direct sales force markets Dey's products to doctors, pharmacies, and wholesalers.

Callisto Pharmaceuticals, Inc. was founded in 1996 and is headquartered in New York, New York. Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The company has three drugs in development, which include SP-304, a guanylyl cyclase C receptor agonist for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome, which has completed Phase I clinical trial; Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activities, which is in Phase II development for advanced carcinoid cancer; and L-Annamycin, a novel compound from the anthracycline family of proven anti-cancer drugs for the treatment of leukemia. It also focuses on the development of Atiprimod for the treatment of rheumatoid arthritis. The company has license agreements with AnorMED Inc. to research, develop, sell, and commercialize the Atiprimod patent rights; and the University of Texas M.D. Anderson Cancer Center to develop and commercialize the L-Annamycin patent rights.

Protalix BioTherapeutics, Inc. ompany was founded in 1993 and is based in Carmiel, Israel. Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Its lead product candidate includes prGCD, a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which is in Phase III clinical trial. The company also develops PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; a proprietary plant cell-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an organophosphate-based pesticide treatment program. Protalix BioTherapeutics, Inc. has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the company's ProCellEx protein expression system; and Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher disease, as well as has a licensing agreement with Icon Genetics AG to license Icon's amplification technology for utilization in the expression of its products.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.